دورية أكاديمية
أعرض في EDS

Improvement of Laboratory Hepatic Parameters After Treatment With 177Lu-DOTATATE: Cohort in an Oncology Reference Center.

التفاصيل البيبلوغرافية
العنوان: Improvement of Laboratory Hepatic Parameters After Treatment With 177Lu-DOTATATE: Cohort in an Oncology Reference Center.
المؤلفون: Dos Santos Soares F; From the Nuclear Medicine Service, and., de Carvalho JR; Abdomen Surgery, National Cancer Institute, Rio de Janeiro, Brazil., de Lima BAM, Felix RCM; From the Nuclear Medicine Service, and., Bulzico DA; From the Nuclear Medicine Service, and., Pujatti PB; From the Nuclear Medicine Service, and.
المصدر: Clinical nuclear medicine [Clin Nucl Med] 2024 Aug 01. Date of Electronic Publication: 2024 Aug 01.
Publication Model: Ahead of Print
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Country of Publication: United States NLM ID: 7611109 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1536-0229 (Electronic) Linking ISSN: 03639762 NLM ISO Abbreviation: Clin Nucl Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Philadelphia, Lippincott.
مستخلص: Purpose: Well-differentiated neuroendocrine neoplasms (NETs) overexpress the somatostatin receptor, which is the target for the peptide receptor radionuclide therapy (PRRT). NETs have a slow growth rate and can metastasize to liver, bone, and lungs. In NETs patients, liver metastasis is an important prognostic marker because liver failure is one of the most common causes of death in this population. In this regard, we aimed to describe the changes in laboratorial parameters in patients submitted to PRRT with 177Lu-DOTATATE, focusing on hepatic parameters.
Patients and Methods: One hundred ten patients treated with 1 to 4 cycles of 7.4 GBq (200 mCi) of 177Lu-DOTATATE from January 2011 to December 2021 were analyzed in this retrospective observational single-center study. Patients were submitted to blood tests before and after each cycle of PRRT. Laboratory measurements were collected to assess liver function, cholestasis, kidney, and bone marrow function.
Results: In the general population (n = 110), ALP (P = 0.013) and GGT (P < 0.001) showed a statistically significant reduction. Patients with high liver disease volume showed a statistically significant reduction in ALT (P = 0.016), whereas patients with low liver disease volume showed a statistically significant reduction in GGT (P = 0.013). All parameters for bone marrow function showed a statistically significant decrease in all population subsets.
Conclusions: Patients treated with 177Lu-DOTATATE showed a significant improvement in liver function and cholestasis parameters, and a consistent decrease in bone marrow function, even in the presence of advanced liver disease.
Competing Interests: Conflicts of interest and sources of funding: none declared.
(Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
References: Inzani F, Rindi G. Introduction to neuroendocrine neoplasms of the digestive system: definition and classification. Pathologica. 2021;113:1–4.
Fortunati E, Argalia G, Zanoni L, et al. New PET radiotracers for the imaging of neuroendocrine neoplasms. Curr Treat Options Oncol. 2022;23:703–720.
Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–135.
Zheng Z, Chen C, Jiang L, et al. Incidence and risk factors of gastrointestinal neuroendocrine neoplasm metastasis in liver, lung, bone, and brain: a population-based study. Cancer Med. 2019;8:7288–7298.
Bagante F, Spolverato G, Merath K, et al. Neuroendocrine liver metastasis: the chance to be cured after liver surgery. J Surg Oncol. 2017;115:687–695.
Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754–2762.
Sampaio IL, Luiz HV, Violante LS, et al. Treatment of gastroenteropancreatic neuroendocrine tumors with 177Lu-DOTA-TATE: experience of the Portuguese Institute of Oncology in Porto. Acta Med Port. 2016;29:726–733.
Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182–188.
de Lima BAM, da Silva RG, Carroll C, et al. Neutrophil to lymphocyte ratio as a prognosis biomarker of PRRT in NET patients. Endocrine. 2022;78:177–185.
Kieft AL, Ibrahim Y, Dyson G, et al. Experience with 177Lu-Dotatate in patients with metastatic gastroenteropancreatic neuroendocrine tumors at a single urban cancer center. Int J Radiat Oncol Bio Phys. 2023;117:e307–e308.
Baum RP, Kulkarni HR, Singh A, et al. Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget. 2018;9:16932–16950.
تواريخ الأحداث: Date Created: 20240801 Latest Revision: 20240801
رمز التحديث: 20240801
DOI: 10.1097/RLU.0000000000005375
PMID: 39087646
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-0229
DOI:10.1097/RLU.0000000000005375